Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) on chronic statin therapy. Patients are randomized into two groups: atorvastatin pre-treatment group (80mg atorvastatin seven days before PCI) and control group (PCI without atorvastatin pretreatment, chronic statin treatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Motol
• Treatments: Atorvastatin; Atorvastatin Calcium; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

• Indication for percutaneous coronary intervention

• Informed consent

• Chronic statin therapy

Exclusion Criteria:

• Acute coronary syndrome in last 14 days

• Renal insufficiency (creatinine more 150 umol/l)

• Diseases severely limiting prognosis

• Previous participation in this study

• Chronic occlusion of the coronary artery, bypass intervention, left main intervention

• Chronic statin treatment with atorvastatin 80mg daily and rosuvastatin